赛趋科：2026个体化疗法新路径：FDA“合理机制”开发框架解析报告（英文版）（18页）.pdf

1、Article PackNavigating the Plausible Mechanism PathwayMay 20262May 2026 Copyright 2026 Citeline,a Norstella company.(Unauthorized photocopying prohibited.)ForewordThe FDAs draft guidance on the plausible mechanism pathway has brought definition to an area of development that,until recently,relied mo

2、re on signals than structure.By outlining how individualized therapies might meet existing evidentiary standards,the agency has given sponsors and stakeholders a clearer reference point for planning,investment,and regulatory engagement.These articles,taken from Pink Sheet,examine how that reference

3、point is being interpreted across the rare disease ecosystem.A central theme across all four articles is timing.For individualized therapies,decisions that might traditionally come later now move upstream.Evidence strategy,manufacturing considerations,and approaches to data collection increasingly n

4、eed to be set as soon as a patient and target are identified.The guidance reflects that reality,emphasizing early planning and robust clinical responses even when patient numbers are extremely limited.We also explore how formal guidance affects real-world decisions.Clearer articulation of FDA thinki

5、ng can alter development trajectories,revive programs that once appeared impractical,and influence how investors assess risk.At the same time,the guidance draws boundaries around what the plausible mechanism framework is designed to support,reducing uncertainty about where flexibility does and does

6、not exist.The collection also highlights ongoing discussion about how the plausible mechanism pathway fits alongside other FDA programs,including platform technology designations.Stakeholders are weighing how these frameworks interact,how evidentiary expectations compare,and how sponsors should navi